On Nov 27, major Wall Street analysts update their ratings for $Alector (ALEC.US)$, with price targets ranging from $3 to $7.
Morgan Stanley analyst Jeffrey Hung downgrades to a sell rating, and adjusts the target price from $10 to $3.
TD Cowen analyst Yaron Werber maintains with a buy rating.
Mizuho Securities analyst Graig Suvannavejh maintains with a buy rating.
H.C. Wainwright analyst Andrew Fein maintains with a buy rating, and adjusts the target price from $35 to $7.
Furthermore, according to the comprehensive report, the opinions of $Alector (ALEC.US)$'s main analysts recently are as follows:
Following the Phase 2 INVOKE-2 study results indicating that AL002 did not decelerate Alzheimer's progression nor affect disease biomarkers, there's a tempered perspective on this drug's immediate potential. Nonetheless, optimism remains for the potential of latozinemab, though the focus may shift more favorably towards other opportunities within the analyst's coverage, pending further data expected from the Phase 3 INFRONT-3 trials in frontotemporal dementia projected around late 2025 or early 2026.
The activation of TREM2 showed limited efficacy in Alzheimer's disease, representing a challenge for the domain of genome-wide association studies-driven medicine. Additionally, the mechanism of ARIA-E may need further evaluation.
Here are the latest investment ratings and price targets for $Alector (ALEC.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月27日，多家華爾街大行更新了$Alector (ALEC.US)$的評級，目標價介於3美元至7美元。
摩根士丹利分析師Jeffrey Hung下調至賣出評級，並將目標價從10美元下調至3美元。
TD Cowen分析師Yaron Werber維持買入評級。
瑞穗證券分析師Graig Suvannavejh維持買入評級。
H.C. Wainwright分析師Andrew Fein維持買入評級，並將目標價從35美元下調至7美元。
此外，綜合報道，$Alector (ALEC.US)$近期主要分析師觀點如下：
隨着第2期INVOKE-2研究結果顯示AL002並未減緩阿爾茨海默病的進展，也未影響疾病生物標誌物，對這種藥物的即期潛力產生了一種謹慎的看法。儘管如此，對latozinemab的潛力仍然持樂觀態度，儘管焦點可能更有利於分析師覆蓋的其他機會，待預計於2025年底或2026年初從額顳型癡呆症第3期INFRONt-3試驗中獲得進一步數據。
TREM2的激活在阿爾茨海默病中顯示出有限的療效，這對基因組關聯研究驅動的醫學領域構成挑戰。此外，ARIA-E的機制可能需要進一步評估。
以下爲今日4位分析師對$Alector (ALEC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
